Eur Respir J:中亚高原居民心功能和肺动脉高压情况

2020-05-27 MedSci原创 MedSci原创

与低海拔居民相比,高原居民长期暴露于缺氧与高PAP以及左右心功能轻微改变有关。根据专家对慢性高海拔疾病的共识定义,在这一大型高原人群中,HAPH的患病率在6%至35%之间变化。

慢性暴露于低氧会增加高员居民的肺动脉压(PAP),但目前对于诊断高海拔肺动脉高压(HAPH)的标准存在争议。近日,呼吸疾病领域权威杂志Eur Respir J上发表了一篇研究文章,研究人员评估了3250 m高原居民的心脏功能和PAP,并使用不同的定义探讨了HAPH患病率。

该研究纳入的中亚高原居民无明显的心肺疾病,永久生活在2500-3500m的高原,而年龄相仿的低海拔居民生活在海拔<800m的地区。参与者在其居住海拔附近(3250m vs. 760m)进行超声心动图检查。

173名参与者(97名高原居民,76名低海拔居民)完成了研究,平均年龄为49±9岁(49%的女性)。低海拔居民与高原居民的结局比较为:组间收缩期PAP(23±5 vs. 30±10 mmHg)、右心室分数变化(42±6 vs. 39±8%)、三尖瓣环平面收缩期偏移(2.1±0.3 vs. 2.0±0.3 cm)、右心房容积指数(20±6 vs. 23±8 mL·m−2)、左心室射血分数(62±4 vs. 57±5%)和搏出量(64±10 vs. 57±11 mL)比较均有p<0.05。根据标准,HAPH患病率介于6%和35%之间。

由此可见,与低海拔居民相比,高原居民长期暴露于缺氧与高PAP以及左右心功能轻微改变有关。根据专家对慢性高海拔疾病的共识定义,在这一大型高原人群中,HAPH的患病率在6%至35%之间变化。

原始出处:

Mona Lichtblau,et al.Cardiac function and pulmonary hypertension in Central Asian highlanders at 3250 m.Eur Respir J.2020.https://erj.ersjournals.com/content/early/2020/04/20/13993003.02474-2019

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1925336, encodeId=4fb01925336e3, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Feb 15 05:37:48 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465703, encodeId=cb8a1465e0396, content=<a href='/topic/show?id=5f5f508933f' target=_blank style='color:#2F92EE;'>#心功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50893, encryptionId=5f5f508933f, topicName=心功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6df96750284, createdName=caobinglei8081, createdTime=Fri May 29 03:37:48 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574869, encodeId=9e2215e4869fb, content=<a href='/topic/show?id=6d6210228935' target=_blank style='color:#2F92EE;'>#高原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102289, encryptionId=6d6210228935, topicName=高原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=687116029883, createdName=jmtang, createdTime=Fri May 29 03:37:48 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1050897, encodeId=61f7105089eb3, content=肺动脉高压表面是罕见病,事实上临床上并不少见,治疗药物虽然有一些,但是整体仍然不理解,可能未来需要采用综合治疗措施。, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=明天jing, createdTime=Wed May 27 15:37:48 CST 2020, time=2020-05-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1925336, encodeId=4fb01925336e3, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Feb 15 05:37:48 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465703, encodeId=cb8a1465e0396, content=<a href='/topic/show?id=5f5f508933f' target=_blank style='color:#2F92EE;'>#心功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50893, encryptionId=5f5f508933f, topicName=心功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6df96750284, createdName=caobinglei8081, createdTime=Fri May 29 03:37:48 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574869, encodeId=9e2215e4869fb, content=<a href='/topic/show?id=6d6210228935' target=_blank style='color:#2F92EE;'>#高原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102289, encryptionId=6d6210228935, topicName=高原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=687116029883, createdName=jmtang, createdTime=Fri May 29 03:37:48 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1050897, encodeId=61f7105089eb3, content=肺动脉高压表面是罕见病,事实上临床上并不少见,治疗药物虽然有一些,但是整体仍然不理解,可能未来需要采用综合治疗措施。, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=明天jing, createdTime=Wed May 27 15:37:48 CST 2020, time=2020-05-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1925336, encodeId=4fb01925336e3, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Feb 15 05:37:48 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465703, encodeId=cb8a1465e0396, content=<a href='/topic/show?id=5f5f508933f' target=_blank style='color:#2F92EE;'>#心功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50893, encryptionId=5f5f508933f, topicName=心功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6df96750284, createdName=caobinglei8081, createdTime=Fri May 29 03:37:48 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574869, encodeId=9e2215e4869fb, content=<a href='/topic/show?id=6d6210228935' target=_blank style='color:#2F92EE;'>#高原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102289, encryptionId=6d6210228935, topicName=高原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=687116029883, createdName=jmtang, createdTime=Fri May 29 03:37:48 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1050897, encodeId=61f7105089eb3, content=肺动脉高压表面是罕见病,事实上临床上并不少见,治疗药物虽然有一些,但是整体仍然不理解,可能未来需要采用综合治疗措施。, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=明天jing, createdTime=Wed May 27 15:37:48 CST 2020, time=2020-05-27, status=1, ipAttribution=)]
    2020-05-29 jmtang
  4. [GetPortalCommentsPageByObjectIdResponse(id=1925336, encodeId=4fb01925336e3, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Feb 15 05:37:48 CST 2021, time=2021-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465703, encodeId=cb8a1465e0396, content=<a href='/topic/show?id=5f5f508933f' target=_blank style='color:#2F92EE;'>#心功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50893, encryptionId=5f5f508933f, topicName=心功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6df96750284, createdName=caobinglei8081, createdTime=Fri May 29 03:37:48 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574869, encodeId=9e2215e4869fb, content=<a href='/topic/show?id=6d6210228935' target=_blank style='color:#2F92EE;'>#高原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102289, encryptionId=6d6210228935, topicName=高原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=687116029883, createdName=jmtang, createdTime=Fri May 29 03:37:48 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1050897, encodeId=61f7105089eb3, content=肺动脉高压表面是罕见病,事实上临床上并不少见,治疗药物虽然有一些,但是整体仍然不理解,可能未来需要采用综合治疗措施。, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=明天jing, createdTime=Wed May 27 15:37:48 CST 2020, time=2020-05-27, status=1, ipAttribution=)]
    2020-05-27 明天jing

    肺动脉高压表面是罕见病,事实上临床上并不少见,治疗药物虽然有一些,但是整体仍然不理解,可能未来需要采用综合治疗措施。

    0

相关资讯

JACC Cardiovasc Interv:英国研究称肺动脉去神经治疗肺动脉高压安全有效!

肺动脉高压不好治,靶向药物也贵,还有什么好办法治疗吗?

Arthritis Rheumatol:TNF在结缔组织病相关性肺动脉高压新模型中可诱发闭塞性肺血管病

TNF-Tg小鼠代表了CTD-PAH的新模型,复制了关键疾病特征,可作为发现和评估治疗方法的有价值工具。

盘点:肺动脉高压(PAH)近期重要研究进展汇总

【1】抑制CHK 1(检查点激酶1)可以治疗肺动脉高压

Front Pharmacol:用于肺动脉高压治疗的药用植物和植物化学物质

肺动脉高压(PH)是一种进行性疾病,与肺动脉重塑、右心室肥大、右心室衰竭以及最终死亡有关。本研究旨在回顾1994年至2019年期间用于PH治疗的药用植物和植物化学物质。

Arterioscler Thromb Vasc Biol:抑制CHK 1(检查点激酶1)可以治疗肺动脉高压

肺动脉高压(PAH)是一种衰弱性疾病,与肺动脉远端血管重塑有关,导致肺动脉压力升高、右心室肥大和死亡。虽然呈现出高水平的DNA损伤,通常会危及其生存能力,但肺动脉平滑肌细胞(PASMCs)从PAH患者

Acceleron的TGF-β配体陷阱Sotatercept治疗肺动脉高压,获得欧洲药品管理局的优先药品(PRIME)称号

2019年,FDA授予sotatercept治疗PAH的孤儿药称号。自EMA在2016年制定该计划以来,Sotatercept是首个获得PRIME认证的肺动脉高压治疗药物。